U.S. Markets closed
  • S&P Futures

    4,403.75
    +0.75 (+0.02%)
     
  • Dow Futures

    34,949.00
    -2.00 (-0.01%)
     
  • Nasdaq Futures

    15,113.50
    +15.50 (+0.10%)
     
  • Russell 2000 Futures

    2,203.10
    -2.00 (-0.09%)
     
  • Crude Oil

    72.29
    +0.22 (+0.31%)
     
  • Gold

    1,801.50
    -0.30 (-0.02%)
     
  • Silver

    25.25
    +0.02 (+0.07%)
     
  • EUR/USD

    1.1776
    +0.0006 (+0.0471%)
     
  • 10-Yr Bond

    1.2860
    +0.0210 (+1.66%)
     
  • Vix

    17.20
    -0.49 (-2.77%)
     
  • GBP/USD

    1.3758
    +0.0004 (+0.0316%)
     
  • USD/JPY

    110.5330
    +0.0230 (+0.0208%)
     
  • BTC-USD

    34,737.93
    +674.36 (+1.98%)
     
  • CMC Crypto 200

    786.33
    -7.40 (-0.93%)
     
  • FTSE 100

    7,027.58
    +59.28 (+0.85%)
     
  • Nikkei 225

    27,548.00
    +159.80 (+0.58%)
     

CorMedix Inc. to Present at the 20th Annual Needham Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

BERKELEY HEIGHTS, N.J., April 07, 2021 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory disease, today announced that CorMedix management will present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference taking place on April 12 – 15, 2021.

20th Annual Needham Virtual Healthcare Conference (virtual)
Date: Wednesday, April 14th
Time: 4:30 pm Eastern Time
Webcast: https://wsw.com/webcast/needham107/crmd/2235068

About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company is focused on developing its lead product DefenCath™, a novel, antibacterial and antifungal solution designed to prevent costly and life-threatening bloodstream infections associated with the use of central venous catheters in patients undergoing chronic hemodialysis. DefenCath has been designated by FDA as Fast Track and as a Qualified Infectious Disease Product, which provides an additional five years of marketing exclusivity, which will be added to the five years granted to a New Chemical Entity upon approval of the NDA. CorMedix also intends to develop DefenCath as a catheter lock solution for use in oncology and total parenteral nutrition patients. It is leveraging its taurolidine technology to develop a pipeline of antimicrobial medical devices, with programs in surgical sutures and meshes, and topical hydrogels. The Company is also working with top-tier researchers to develop taurolidine-based therapies for rare pediatric cancers. Neutrolin® is CE Marked and marketed in Europe and other territories as a medical device. For more information, visit: www.cormedix.com.

Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
617-430-7576